STOCK TITAN

Vanguard disaggregates holdings; reports 0 shares in Collegium (COLL)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Collegium Pharmaceutical Inc amendment: The Vanguard Group reports 0 shares beneficially owned of Collegium common stock following an internal realignment. The filing states that certain Vanguard subsidiaries will report ownership separately in accordance with SEC Release No. 34-39538 (January 12, 1998).

The disclosure lists 0 shares and 0% voting and dispositive power in the issuer’s common stock and is signed by Vanguard’s Head of Global Fund Administration.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings; beneficial ownership now zero.

The Vanguard Group states its internal realignment caused certain subsidiaries to report separately, and it no longer is deemed to beneficially own the securities formerly reported under the parent. The filing cites January 12, 1998 SEC Release No. 34-39538.

Cash-flow treatment and any subordinate holder quantities are not listed; subsequent filings by the disaggregated entities may show new beneficial ownership entries.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does Vanguard’s Schedule 13G/A say about COLL ownership?

It states that The Vanguard Group reports 0 shares beneficially owned of Collegium common stock, with 0% voting and dispositive power, following an internal reorganization and disaggregation of subsidiary holdings.

Why did Vanguard change its ownership reporting for COLL?

Vanguard explains an internal realignment occurred on January 12, 2026, and per SEC Release No. 34-39538 (January 12, 1998) certain subsidiaries will report beneficial ownership separately from the parent entity.

Does this filing show any shares held by Vanguard subsidiaries?

This amendment reports only that the parent entity has 0 shares; it does not list subsidiary holdings. Separate filings by the disaggregated subsidiaries would disclose any shares they beneficially own.

Who signed the amendment and when was it filed?

The form is signed by Ashley Grim, Head of Global Fund Administration and dated 03/26/2026. The filing’s exhibit header shows 03/13/2026 as the entry date in the document.
Collegium Pharmaceutical Inc

NASDAQ:COLL

View COLL Stock Overview

COLL Rankings

COLL Latest News

COLL Latest SEC Filings

COLL Stock Data

1.06B
31.05M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
STOUGHTON